Epix Delaware, Inc.

The Trustees of Boston College

Nanotherapeutics, Inc.

Cytopathfinder, Inc.

Predix Pharmaceuticals Holdings, Inc.

Dongli Chen

Yael Marantz

Oren Becker

Dale S Dhanoa

Silvia Noiman

Boaz Inbal

Sharon Shacham

Shay Bar-Haim

Alexander Heifetz

Pradyumna Mohanty

Srinivasa Rao Cheruku

Mercedes Lobera

Anurag Sharadendu

Laurence Wu

Merav Fichman

Raphael Nudelman

Venkitasamy Kesavan

Sharon Shachem

Shomir Ghosh

Jian Lin

Zhaoda Zhang

Steffi Koerner

Efrat Ben-Zeev

Rosa Melendez

A Sekar Reddy

Larry W McLaughlin

Rosa E Melendez

Sekar A Reddy

Rosa E Mele'ndez

Andrew W Fraley

Tao Lan

Sekar Reddy Alla

Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein. 

Carboxamide compounds and their use

The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Thienopyridinone compounds and methods of treatment

The invention relates to 5-HT receptor modulators, particularly 5-HTantagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

Piperidinylamino-thieno[2,3-D] pyrimidine compounds

The invention generally relates to thienopyridinone 5-HTreceptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.

Compositions and methods for treating CNS disorders

Synthesis of thienopyridinone compounds and related intermediates

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Arylpiperazinyl compounds

The invention relates to 5-HT receptor agonists and partial agonists. Thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

The invention relates to 5-HTreceptor agonists and partial agonists. Thienopyridinone compounds and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HTreceptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, Parkinson's disease, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, and nonulcer dyspepsia. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno[2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as anxiety, depression, schizophrenia, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Piperidinylamino-thieno[2,3-d] pyrimidine compounds

The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3'-dideoxy-&#x3b2;-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an 'O2 carbonyl', that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.

Selective anti-viral nucleoside chain terminators

Growing community of inventors

Brighton, MA, United States of America

Dongli Chen